# AnaptysBio Shares Rise After FDA Expands Jemperli Approval

By Riza Dagoc

Canonical URL: https://www.tokenpost.com/news/regulation/35154
Published: 2026-10-20T00:41:38.000Z
Updated: 2026-10-20T00:41:38.000Z
Section: Regulation

> The accelerated approval adds a use for GSK’s cancer treatment in a type of rectal cancer.

AnaptysBio shares rose Monday, Oct. 19, after the U.S. Food and Drug Administration (FDA) expanded approval of GSK’s Jemperli for a type of rectal cancer through its accelerated pathway.

The decision adds a use to the label for Jemperli, an anti-PD-1 cancer treatment. AnaptysBio is GSK’s partner on the drug.